What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CLN-049 will be initiated using two step-up doses (SUDs), followed by the first target dose (TD) one week later, and weekly thereafter.”In the company’s words, NCT07722767 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML, AML (Acute Myeloid Leukemia)
- Main trialPhase 1/2
- “CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)”In the company’s words, NCT05143996 on ClinicalTrials.gov
Other drugs for Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up2
- 30 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Dec 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Dec 2029 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | |
| Phase 1Not yet recruiting | 30 Sep 2027 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026